Spironolactone oral suspension is an antagonist of aldosterone indicated for:
• the treatment of NYHA Class III to lV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1)
• use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2)
• the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions (1.3)
